The impact of surgery and anesthesia on post-operative cognitive decline and Alzheimer's disease development: Biomarkers and preventive strategies

Journal of Alzheimer's Disease

Volumn 41, Issue 1, 2014, Pages 1-13

  Kapila, Ayush K ^a   Watts, Helena R ^a   Wang, Tianlong ^b   Ma, Daqing ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; anesthesia; cognitive decline; neuroinflammation; surgery

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ATORVASTATIN; BIOLOGICAL MARKER; CELASTROL; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DONEPEZIL; GALANTAMINE; HUPERZINE A; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; STEROID; TACRINE; TAU PROTEIN; UBIDECARENONE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANESTHESIA; CEREBROSPINAL FLUID; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; DISEASE COURSE; DISEASE PREDISPOSITION; EXCITOTOXICITY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTOPERATIVE COGNITIVE DECLINE; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; SYNAPTIC MEMBRANE; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION; ANIMAL; COGNITION DISORDERS; METABOLISM; POSTOPERATIVE COMPLICATION;

ALZHEIMER DISEASE; ANESTHESIA; ANIMALS; BIOLOGICAL MARKERS; COGNITION DISORDERS; HUMANS; NEUROPROTECTIVE AGENTS; POSTOPERATIVE COMPLICATIONS;

EID: 84902240048     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132258     Document Type: Review

References (145)

1. Hebert LE, Bienias JL, Aggarwal NT, Wilson RS, Bennett DA, Shah RC, Evans DA (2010) Changeinrisk of Alzheimer disease over time. Neurology 75, 786-791.
2. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S4-S9.
3. Hebert LE, Beckett LA, Scherr PA, Evans DA (2001) Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15, 169-173.
4. Rockwood K, Wallack M, Tallis R (2003) The treatment of Alzheimer's disease: Success short of cure. Lancet Neurol 2, 630-633.
5. Thies W, Bleiler L (2011) 2011 Alzheimer's disease facts and figures. Alzheimers Dement 7, 208-244.
6. Bekker AY, Weeks EJ (2003) Cognitive function after anaesthesia in the elderly. Best Pract Res Clin Anaesthesiol 17, 259-272.
7. Rasmussen LS, ISPOCD2 investigators (2005) Postoperative cognitive dysfunction in the elderly. Acta Anaesthesiol Scand 49, 1573.
8. Ologunde R, Ma D (2011) Do inhalational anesthetics cause cognitive dysfunction? Acta Anaesthesiol Taiwan 49, 149-153.
9. Rudolph JL, Schreiber KA, Culley DJ, McGlinchey RE, Crosby G, Levitsky S, Marcantonio ER (2010) Measurement of post-operative cognitive dysfunction after cardiac surgery: A systematic review. Acta Anaesthesiol Scand 54, 663-677.
10. Silverstein JH, Timberger M, Reich DL, Uysal S (2007) Central nervous system dysfunction after noncardiac surgery and anesthesia in the elderly. Anesthesiology 106, 622-628.
11. Fidalgo AR, Cibelli M, White JPM, Nagy I, Noormo-hamed F, Benzonana L, Maze M, Ma D (2011) Peripheral orthopaedic surgery down-regulates hippocampal brain-derived neurotrophic factor and impairs remote memory in mouse. Neuroscience 190, 194-199.
12. Canet J, Raeder J, Rasmussen LS, Enlund M, Kuipers HM, Hanning CD, Jolles J, Korttila K, Siersma VD, Dodds C, Abildstrom H, Sneyd JR, Vila P, Johnson T, Munoz Corsini L, Silverstein JH, Nielsen IK, Moller JT, ISPOCD2 investigators (2003) Cognitive dysfunction after minor surgery in the elderly. Acta Anaesthesiol Scand 47, 1204-1210.
13. Kline RP, Pirraglia E, Cheng H, De Santi S, Li Y, Haile M, de Leon MJ, Bekker A, Alzheimer's Disease Neuroimaging, Initiative (2012) Surgery and brain atrophy in cognitively normal elderly subjects and subjects diagnosed with mild cognitive impairment. Anesthesiology 116, 603-612.
14. Lee TA, Wolozin B, Weiss KB, Bednar MM (2005) Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis 7, 319-324.
15. Plassman BL, Langa KM, Finlayson EVA, Rogers MAM (2009) Surgery using general anesthesia and risk of dementia in the aging, demographics and memory study. Alzheimers Dement 5, 3-153.
16. Vanderweyde T, Bednar MM, Forman SA, Wolozin B (2010) Iatrogenic risk factors for Alzheimer's disease: Surgery and anesthesia. J Alzheimers Dis 22 (Suppl 3), 91-104.
17. Bekker A, Lee C, deSanti S, Pirraglia E, Zaslavsky A, Farber S, Haile M, de Leon MJ (2010) Does mild cognitive impairment increase the risk of developing postoperative cognitive dysfunction? Am J Surg 199, 782-788.
18. Sprung J, Jankowski CJ, Roberts RO, Weingarten TN, Aguilar AL, Runkle KJ, Tucker AK, McLaren KC, Schroeder DR, Hanson AC, Knopman DS, Gurrieri C, Warner DO (2013) Anesthesia and incident dementia: A population-based, nested, case-control study. Mayo Clin Proc 88, 552-561.
19. Sztark F, Le Goff M, André D, Ritchie K, Dartigues J, Helmer C (2013) Exposure to general anaesthesia could increase the risk of dementia in elderly: 18AP1-4. Eur J Anaesthesiol 30, 245-245.
20. Dabrowski W, Rzecki Z, Czajkowski M, Pilat J, Wacinski P, Kotlinska E, Sztanke M, Sztanke K, Stazka K, Pasternak K (2012) Volatile anesthetics reduce biochemical markers of brain injury and brain magnesium disorders in patients undergoing coronary artery bypass graft surgery. J Cardio-thorac Vasc Anesth 26, 395-402.
21. Fung A, Vizcaychipi M, Lloyd D, Wan Y, Ma D (2012) Central nervous system inflammationin disease related conditions: Mechanistic prospects. Brain Res 1446, 144-155.
22. Eikelenboom P, Veerhuis R, Van Exel E, JM Hoozemans J, JM Rozemuller A, A van Gool W (2011) The early involvement of the innate immunity in the pathogenesis of lateonset alzheimers disease: neuropathological, epidemiological and genetic evidence. Current Alzheimer Research 8, 142-150.
23. Fodale V, Santamaria LB, Schifilliti D, Mandal PK (2010) Anaesthetics and postoperative cognitive dysfunction: A pathological mechanism mimicking Alzheimer's disease. Anaesthesia 65, 388-395.
24. Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, Gravenstein JS (2008) Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology 108, 18-30.
25. Hu Z, Ou Y, Duan K, Jiang X (2010) Inflammation: A bridge between postoperative cognitive dysfunction and Alzheimer's disease. Med Hypotheses 74, 722-724.
26. Koepsell TD, Kurland BF, Harel O, Johnson EA, Zhou XH, Kukull WA (2008) Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology 70, 1732-1739.
27. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
28. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862.
29. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102.
30. Fidalgo AR, Cibelli M, White JPM, Nagy I, Maze M, Ma D (2011) Systemic inflammation enhances surgery-induced cognitive dysfunction in mice. Neurosci Lett 498, 63-66.
31. Grab DJ, Chakravorty SJ, van der Heyde H, Stins MF (2011) How can microbial interactions with the blood-brain barrier modulate astroglial and neuronal function? Cell Microbiol 13, 1470-1478.
32. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tav-ernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, European Alzheimer's Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Lev-eillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Gal-imberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeck-hoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
33. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muh-leisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
34. Wan Y, Xu J, Meng F, Bao Y, Ge Y, Lobo N, Vizcaychipi MP, Zhang D, Gentleman SM, Maze M, Ma D (2010) Cognitive decline following major surgery is associated with gliosis, beta-amyloid accumulation, and tau phosphorylation in old mice. Crit Care Med 38, 2190-2198.
35. Mrak RE, Griffin WST (2005) Glia and their cytokines in progression ofneurodegeneration. Neurobiol Aging 26, 349-354.
36. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28, 8354-8360.
37. Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, Dickson DW (2007) Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohisto-chemistry. J Histochem Cytochem 55, 687-700.
38. Farina C, Aloisi F, Meinl E (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol 28, 138-145.
39. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV (2004) Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24, 2143-2155.
40. Tang JX, Baranov D, Hammond M, Shaw LM, Eckenhoff MF, Eckenhoff RG (2011) Human Alzheimerand inflammation biomarkers after anesthesia and surgery. Anesthesiology 115, 727-732.
41. Blalock EM, Chen KC, Stromberg AJ, Norris CM, Kadish I, Kraner SD, Porter NM, Landfield PW (2005) Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: Statistical reliability and functional correlation. Ageing Res Rev 4, 481-512.
42. Streit WJ, Braak H, Xue QS, Bechmann I (2009) Dys-trophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurode-generation in Alzheimer's disease. Acta Neuropathol 118, 475-485.
43. van Gool WA, Aisen PS, Eikelenboom P (2003) Anti-inflammatory therapy in Alzheimer's disease: Is hope still alive? J Neurol 250, 788-792.
44. Hoozemans JJ, Rozemuller AJ, van Haastert ES, Eike-lenboom P, van Gool WA (2011) Neuroinflammation in Alzheimer's disease wanes with age. J Neuroinflammation 8, 171.
45. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134-147.
46. Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69, 155-167.
47. Sultana R, Butterfield DA (2010) Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19, 341-353.
48. Praticò D (2008) Evidenceofoxidative stressinAlzheimer's disease brain and antioxidant therapy. Ann N Y Acad Sci 1147, 70-78.
49. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71, 621s-629s.
50. McDonald DR, Brunden KR, Landreth GE (1997) Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 17, 2284-2294.
51. Xie H, Hou S, Jiang J, Sekutowicz M, Kelly J, Bacskai BJ (2013) Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci USA 110, 7904-7909.
52. Mandal PK, Tripathi M, Sugunan S (2012) Brain oxidative stress: Detection and mapping of anti-oxidant marker 'Glu-tathione'in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 417, 43-48.
53. Resende R, Moreira PI, Proença T, Deshpande A, Busciglio J, Pereira C, Oliveira CR (2008) Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44, 2051-2057.
54. Schrag M, Mueller C, Zabel M, Crofton A, Kirsch W, Ghribi O, Squitti R, Perry G (2013) Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis. Neurobiol Dis 59, 100-110.
55. Kücükakin B, Gögenur I, Reiter RJ, Rosenberg J (2009) Oxidative stress in relation to surgery: Is there a role for the antioxidant melatonin? J Surg Res 152, 338-347.
56. Ruzic B, Tomaskovic I, Trnski D, Kraus O, Bekavac-Beslin M, Vrkic N (2005) Systemic stress responses in patients undergoing surgery for benign prostatic hyperplasia. BJU Int 95, 77-80.
57. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
58. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shep-ardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
59. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
60. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK (2010) Co-occurrence of Alzheimer's disease fj-amyloid and tau pathologies at synapses. Neurobiol Aging 31, 1145-1152.
61. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
62. John JP, Sunyer B, Hoger H, Pollak A, Lubec G (2009) Hippocampal synapsin isoform levels are linked to spatial memory enhancement by SGS742. Hippocampus 19, 731-738.
63. Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR (1996) Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol 25, 821-828.
64. Hunt CA, Schenker LJ, Kennedy MB (1996) PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. JNeurosci 16, 1380-1388.
65. Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK (2010) Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci 30, 14299-14304.
66. Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM (2004) Synaptic changes in Alzheimer's disease: Increased amyloid-fj and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 165, 1809-1817.
67. Stellwagen D, Malenka RC (2006) Synaptic scaling mediated by glial TNF-alpha. Nature 440, 1054-1059.
68. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Mar-tino G (2010) The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 17, 1083-1091.
69. Norden DM, Godbout JP (2013) Review: Microglia of the aged brain: Primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 39, 19-34.
70. Chapman TR, Barrientos RM, Ahrendsen JT, Hoover JM, Maier SF, Patterson SL (2012) Aging and infection reduce expression of specific brain-derived neurotrophic factor mRNAs in hippocampus. Neurobiol Aging 33, 832.e1-832.14.
71. Chapman TR, Barrientos RM, Ahrendsen JT, Maier SF, Patterson SL (2010) Synaptic correlates of increased cognitive vulnerability with aging: Peripheral immune challenge and aging interact to disrupt theta-burst late-phase long-term potentiation in hippocampal area CA1. J Neurosci 30, 7598-7603.
72. Cortese GP, Barrientos RM, Maier SF, Patterson SL (2011) Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneu-rosomes. J Neurosci 31, 4274-4279.
73. Barrientos RM, Frank MG, Crysdale NY, Chapman TR, Ahrendsen JT, Day HE, Campeau S, Watkins LR, Patterson SL, Maier SF (2011) Little exercise, big effects: Reversing aging and infection-induced memory deficits, and underlying processes. J Neurosci 31, 11578-11586.
74. Barrientos RM, Hein AM, Frank MG, Watkins LR, Maier SF (2012) Intracisternal interleukin-1 receptor antagonist prevents postoperative cognitive decline and neuroinflammatory response in aged rats. J Neurosci 32, 14641-14648.
75. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, Hutchinson P, Grainger S, King A, Hopkins SJ, Rothwell N, Tyrrell P (2011) Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: Results of a dose-ranging study. J Cereb Blood Flow Metab 31, 439-447.
76. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63, 901-910.
77. O'Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330, 157-160.
78. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830, 226-236.
79. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131, 651-664.
80. Serrano GE, Lelutiu N, Rojas A, Cochi S, Shaw R, Makinson CD, Wang D, FitzGerald GA, Dingledine R (2011) Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci31, 14850-14860.
81. Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, Jellinger K, Tragl KH, Fischer P (2010) Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry 18, 973-982.
82. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Afj causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
83. Solomon B (2007) Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 16, 819-828.
84. Golde TE, Das P, Levites Y (2009) Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets 8, 31-49.
85. Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M (2012) The presence of Abeta seeds, and not age per se, is critical to the initiation of Abeta deposition in the brain. Acta Neuropathol 123, 31-37.
86. Vizcaychipi MP, Watts HR, O'Dea KP, Lloyd DG, Penn JW, Wan Y, Pac-Soo C, Takata M, Ma D (2013) The therapeutic potential of atorvastatin in a mouse model of postoperative cognitive decline. Ann Surg doi: 10.1097/SLA.0000000000000257
87. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtz-man DM (2005) Synaptic activity regulates interstitial fluid amyloid-fj levels in vivo. Neuron 48, 913-922.
88. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging, Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
89. Gouras GK, Almeida CG, Takahashi RH (2005) Intraneu-ronal Afj accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 26, 1235-1244.
90. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Afj immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the protea-some. Neuron 43, 321-332.
91. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
92. Bajenaru O, Tiu C, Antochi F, Roceanu A (2012) Neurocog-nitive disorders in DSM 5 project-Personal comments. J Neurol Sci 322, 17-19.
93. Ganguli M, Blacker D, Blazer DG, Grant I, Jeste DV, Paulsen JS, Petersen RC, Sachdev PS (2011) Classification of neu-rocognitive disorders in DSM-5: A work in progress. Am J Geriatr Psychiatry 19, 205-210.
94. Mandal PK, Akolkar H, Tripathi M (2012) Mapping of hip-pocampal pH and neurochemicals from in vivo multi-voxel 31 P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis 31, S75-S86.
95. Reinsfelt B, Westerlind A, Blennow K, Zetterberg H, Rick-sten SE (2013) Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid beta. Acta Anaesthesiol Scand 57, 82-88.
96. Avidan MS, Searleman AC, Storandt M, Barnett K, Van-nucci A, Saager L, Xiong C, Grant EA, Kaiser D, Morris JC, Evers AS (2009) Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology 111, 964-970.
97. Newman S, Stygall J, Hirani S, Shaefi S, Maze M (2007) Postoperative cognitive dysfunction after noncardiac surgery: A systematic review. Anesthesiology 106, 572-590.
98. Mason SE, Noel-Storr A, Ritchie CW (2010) The impact of general and regional anesthesia on the incidence of postoperative cognitive dysfunction and post-operative delirium: A systematic review with meta-analysis. J Alzheimers Dis 22 (Suppl 3), 67-79.
99. Guay J (2011) General anaesthesia does not contribute to long-term post-operative cognitive dysfunction in adults: A meta-analysis. Indian J Anaesth 55, 358-363.
100. Evered L, Scott DA, Silbert B, Maruff P (2011) Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. Anesth Analg 112, 1179-1185.
101. Moller J, Cluitmans P, Rasmussen L, Houx P, Rasmussen H, Canet J, Rabbitt P, Jolles J, Larsen K, Hanning C, Langeron O, Johnson T, Lauven P, Kristensen P, Biedler A, van Beem H, Fraidakis O, Silverstein J, Beneken J, Gravenstein J (1998) Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study. Lancet 351, 857-861.
102. Ballard C, Jones E, Gauge N, Aarsland D, Nilsen OB, Saxby BK, Lowery D, Corbett A, Wesnes K, Katsaiti E, Arden J, Amoako D, Prophet N, Purushothaman B, Green D (2012) Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. PLoS One 7, e37410.
103. Mandal PK, Fodale V (2009) Isoflurane and desflurane at clinically relevant concentrations induce amyloid fj-peptide oligomerization: An NMR study. Biochem Biophys Res Commun 379, 716-720.
104. Mandal PK, Simplaceanu V, Fodale V (2010) Intravenous anesthetic diazepam does not induce amyloid-fj peptide oligomerization but diazepam co-administered with halothane oligomerizes amyloid-fj peptide: An NMR Study. J Alzheimers Dis 20, 127-134.
105. Mandal PK, Bhavesh NS, Chauhan VS, Fodale V (2010) NMR investigations of amyloid-fj peptide interactions with propofol at clinically relevant concentrations with and without aqueous halothane solution. J Alzheimers Dis 21, 1303-1309.
106. Wei H, Xie Z (2009) Anesthesia, calcium homeostasis and Alzheimer's disease. Curr Alzheimer Res 6, 30-35.
107. Liang G, Wang Q, Li Y, Kang B, Eckenhoff MF, Eckenhoff RG, Wei H (2008) A presenilin-1 mutation renders neurons vulnerable to isoflurane toxicity. Anesth Analg 106, 492-500, table of contents.
108. Fidalgo AR, Cibelli M, White JP, Nagy I, Wan Y, Ma D (2012) Isoflurane causes neocortical but not hippocampal-dependent memory impairment in mice. Acta Anaesthesiol Scand 56, 1052-1057.
109. Wei H, Kang B, Wei W, Liang G, Meng QC, Li Y, Eckenhoff RG (2005) Isoflurane and sevoflurane affect cell survival and BCL-2/BAX ratio differently. Brain Res 1037, 139-147.
110. Zhang B, Tian M, Zheng H, Zhen Y, Yue Y, Li T, Li S, Mar-cantonio ER, Xie Z (2013) Effects of anesthetic isoflurane and desflurane on human cerebrospinal fluid abeta and tau level. Anesthesiology 119, 52-60.
111. Fodale V, Quattrone D, Trecroci C, Caminiti V, Santamaria LB (2006) Alzheimer's disease and anaesthesia: Implications for the central cholinergic system. Br J Anaesth 97, 445-452.
112. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF (2004) Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 101, 703-709.
113. Pepeu G, Giovannini MG (2010) Cholinesterase inhibitors and memory. Chem Biol Interact 187, 403-408.
114. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (1), CD005593.
115. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14, 704-715.
116. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev (2), CD003154.
117. Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, Sano M, Stern Y (2013) Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimers Dement 9, 733-740.
118. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ (2009) Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: An updated meta-analysis. J Neural Transm 116, 457-465.
119. Ha GT, Wong RK, Zhang Y (2011) Huperzine a as potential treatment of Alzheimer's disease: An assessment on chemistry, pharmacology, and clinical studies. Chem Bio-divers 8, 1189-1204.
120. Small G, Bullock R (2011) Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement7, 177-184.
121. Benveniste EN, Nguyen VT, O'Keefe GM (2001) Immunological aspects of microglia: Relevance to Alzheimer's disease. Neurochem Int 39, 381-391.
122. Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: A pathological perspective. J Neuroin-flammation 1, 14.
123. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cap-pell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68, 930-941.
124. Lampron A, Gosselin D, Rivest S (2011) Targeting the hematopoietic system for the treatment of Alzheimer's disease. Brain Behav Immun 25 (Supplement 1), S71-S79.
125. Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S (2009) Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 132, 1078-1092.
126. Horch HW, Katz LC (2002) BDNF release from single cells elicits local dendritic growth in nearby neurons. Nat Neu-rosci 5, 1177-1184.
127. Lu B (2003) BDNF and activity-dependent synaptic modulation. Learn Mem 10, 86-98.
128. Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10, 209-219.
129. Etminan M, Gill S, Samii A (2003) Effect of non-steroidal anti-inflammatory drugs onrisk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ327, 128.
130. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28, 639-647.
131. Jaturapatporn D, Isaac MG, McCleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2, CD006378.
132. Katsouri L, Vizcaychipi MP, McArthur S, Harrison I, Suarez-Calvet M, Lleo A, Lloyd DG, Ma D, Sastre M (2013) Prazosin, an a1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34, 1105-1115.
133. Vizcaychipi MP, Xu L, Barreto GE, Ma D, Maze M, Giffard RG (2011) Heat shock protein 72 overexpression prevents early postoperative memory decline after orthopedic surgery under general anesthesia in mice. Anesthesiology 114, 891-900.
134. Vizcaychipi MP, Lloyd DG, Wan Y, Palazzo MG, Maze M, Ma D (2011) Xenon pretreatmentmay prevent earlymemory decline after isoflurane anesthesia and surgeryinmice. PLoS One 6, e26394.
135. Pac-Soo C, Lloyd DG, Vizcaychipi MP, Ma D (2011) Statins: The role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis 27, 1-10.
136. Abd TT, Jacobson TA (2011) Statin-induced myopathy: A review and update. Expert Opin Drug Saf 10, 373-387.
137. Asbach P, Paetsch I, Stawowy P, Sander B, Fleck E (2009) Statin-associated focal myositis. Int J Cardiol 133, e33-e34.
138. Law M, Rudnicka AR (2006) Statin safety: A systematic review. Am J Cardiol 97, 52C-60C.
139. Littarru GP, Langsjoen P (2007) Coenzyme Q10 and statins: Biochemical and clinical implications. Mitochondrion 7 (Suppl), S168-174.
140. Allison AC, Cacabelos R, Lombardi VRM, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry 25, 1341-1357.
141. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7, 17-2094-7-17.
142. Nakamichi K, Kitani H, Takayama-Ito M, Morimoto K, Kurane I, Saijo M (2010) Celastrol suppresses morphological and transcriptional responses in microglial cells upon stimulation with double-stranded RNA. Int J Neurosci 120, 252-257.
143. Mecocci P, Polidori MC (2012) Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 1822, 631-638.
144. Guo C, Wang T, Zheng W, Shan Z, Teng W, Wang Z (2013) Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34, 562-575.
145. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115, 2774-2783.